---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-094102"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:53:56.815559+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempest reports Q2 2024 financials; amezalpat shows 6-month survival benefit in liver cancer study

## Summary
- Amezalpat median OS 21 months vs 15 months control (6-month improvement); HR 0.65 stable from prior 0.59.
- Company plans to advance amezalpat into a registrational Phase 3 study in first-line HCC.
- TPST-1495 to enter Phase 2 in Familial Adenomatous Polyposis in 2024 under NCI funding.
- Q2 2024 net loss $9.6M ($0.42 per share); cash and equivalents $31.1M as of June 30, 2024.
- R&D expenses $5.8M in Q2 2024 vs $4.4M in Q2 2023, increase due to CRO costs and stock compensation.

## SEC filing metadata
- accession: 0000950170-24-094102
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017024094102/0000950170-24-094102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017024094102/tpst-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-094102
- JSON: https://secwatch.observer/filing/0000950170-24-094102.json
- Plain text: https://secwatch.observer/filing/0000950170-24-094102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.